Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ying-Jun Chang

Showing results (121-130 of 236) with videos related to

Pageof 24
Sort By:
Clinical Immunology (Orlando, Fla.)|May 22, 2019
Delay expression of NKp30 on NK cells correlates with long-term mycophenolate mofetil treatment and higher EBV viremia post allogenic hematological stem cells transplantationXing-Xing Yu, Xun-Hong Cao, Hong Yan, et al.
British Journal of Haematology|March 13, 2025
Monitoring the KMT2A gene post-chemotherapy independently predicts the relapse and survival risk after allogeneic haematopoietic stem cell transplantationJing Liu, Xiao-Su Zhao, Ying-Jun Chang, et al.
Cancer Immunology, Immunotherapy : CII|April 11, 2025
The effect of TIGIT and PD1 expression on T cell function and prognosis in adult patients with acute myeloid leukemia at diagnosisDai-Hong Xie, Si-Qi Li, Kai Sun, et al.
BMC Cancer|January 4, 2022
Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndromeJun Kong, Meng-Ge Gao, Ya-Zhen Qin, et al.
HLA|November 20, 2023
The impact of donor-specific anti-HLA antibody levels on primary poor graft function and graft rejection in rituximab desensitized haploidentical stem cell transplantationJing Liu, Xiang-Yu Zhao, Lan-Ping Xu, et al.
Blood Advances|December 24, 2019
Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantationXiang-Yu Zhao, Xing-Xing Yu, Zheng-Li Xu, et al.
Annals of Hematology|January 8, 2021
Allogeneic hematopoietic stem cell transplantation for intermediate-risk acute myeloid leukemia in the first remission: outcomes using haploidentical donors are similar to those using matched siblingsYan-Ru Ma, Lan-Ping Xu, Xiao-Hui Zhang, et al.
Annals of Hematology|July 9, 2015
The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantationYu-Qian Sun, Gan-Lin He, Ying-Jun Chang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 25, 2013
Association of an impaired bone marrow microenvironment with secondary poor graft function after allogeneic hematopoietic stem cell transplantationYuan Kong, Ying-Jun Chang, Ya-Zhe Wang, et al.
Blood|April 27, 2012
The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remissionXiao-Jun Huang, Hong-Hu Zhu, Ying-Jun Chang, et al.
Pageof 24

Showing results (121-130 of 236) with videos related to

Sort By:
Pageof 24
Clinical Immunology (Orlando, Fla.)|May 22, 2019
Delay expression of NKp30 on NK cells correlates with long-term mycophenolate mofetil treatment and higher EBV viremia post allogenic hematological stem cells transplantationXing-Xing Yu, Xun-Hong Cao, Hong Yan, et al.
British Journal of Haematology|March 13, 2025
Monitoring the KMT2A gene post-chemotherapy independently predicts the relapse and survival risk after allogeneic haematopoietic stem cell transplantationJing Liu, Xiao-Su Zhao, Ying-Jun Chang, et al.
Cancer Immunology, Immunotherapy : CII|April 11, 2025
The effect of TIGIT and PD1 expression on T cell function and prognosis in adult patients with acute myeloid leukemia at diagnosisDai-Hong Xie, Si-Qi Li, Kai Sun, et al.
BMC Cancer|January 4, 2022
Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndromeJun Kong, Meng-Ge Gao, Ya-Zhen Qin, et al.
HLA|November 20, 2023
The impact of donor-specific anti-HLA antibody levels on primary poor graft function and graft rejection in rituximab desensitized haploidentical stem cell transplantationJing Liu, Xiang-Yu Zhao, Lan-Ping Xu, et al.
Blood Advances|December 24, 2019
Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantationXiang-Yu Zhao, Xing-Xing Yu, Zheng-Li Xu, et al.
Annals of Hematology|January 8, 2021
Allogeneic hematopoietic stem cell transplantation for intermediate-risk acute myeloid leukemia in the first remission: outcomes using haploidentical donors are similar to those using matched siblingsYan-Ru Ma, Lan-Ping Xu, Xiao-Hui Zhang, et al.
Annals of Hematology|July 9, 2015
The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantationYu-Qian Sun, Gan-Lin He, Ying-Jun Chang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 25, 2013
Association of an impaired bone marrow microenvironment with secondary poor graft function after allogeneic hematopoietic stem cell transplantationYuan Kong, Ying-Jun Chang, Ya-Zhe Wang, et al.
Blood|April 27, 2012
The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remissionXiao-Jun Huang, Hong-Hu Zhu, Ying-Jun Chang, et al.
Pageof 24